Author

M. Trisal

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:proteomics· 2 Assay:DNA methylation· 1 Approach:genetic perturbation / CRISPR· 1 Assay:metagenomics· 1

Frequent Co-Authors

B. Pulendran· 2 shared C. Li· 2 shared P. S Arunachalam· 2 shared A. C. Walls· 1 shared A. G. White· 1 shared A. R. Henry· 1 shared A. Zhu· 1 shared B. Fiala· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

B. Pulendran

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Inhibition of CHK2 dependent DNA damage response suppresses Zika virus infection through a STING dependent mechanism

H. Ma, C. Li, Y. Wang, E. V. Valore, M. Trisal, H. Sai-yin Hui, P. Hakimpour, J. R. Bowen, T. W. Mak, M. S. Suthar, B. Pulendran

This study shows that inhibiting CHK2 reduces ZIKV production and rescues developmental defects by enhancing STING-dependent antiviral responses.

bioRxiv · Oct 3, 2022 · PreprintImmunology

Durability of immune responses to the BNT162b2 mRNA vaccine

M. Suthar, P. S Arunachalam, M. Hu, N. Reis, M. Trisal, O. Raeber, S. Chinthrajah, M. E. Davis-Gardner, K. Manning, P. Mudvari, S. Godbole, E. Boritz, A. R. Henry, D. Douek, K. Nadeau, , P. Halfmann

This study shows that antibody and T cell responses to the BNT162b2 vaccine wane significantly at 6 months, suggesting a potential need for a third booster dose.

bioRxiv · Sep 30, 2021Immunology

Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates

P. S Arunachalam, A. C. Walls, N. Golden, C. Atyeo, S. Fischinger, C. Li, P. Aye, M. J. Navarro, L. Lai, V. V. Edara, K. Roltgen, K. Rogers, L. Shirreff, D. E. Ferrell, S. Wrenn, , Coffma

This study evaluates adjuvants for a subunit SARS-CoV-2 nanoparticle vaccine in non-human primates, showing durable neutralizing antibody responses and protection against infection.

bioRxiv · Feb 10, 2021 · PreprintImmunology